X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs STRIDES SHASUN LTD - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD STRIDES SHASUN LTD MERCK LTD/
STRIDES SHASUN LTD
 
P/E (TTM) x 46.4 41.1 112.9% View Chart
P/BV x 7.0 1.0 686.1% View Chart
Dividend Yield % 0.4 1.0 41.6%  

Financials

 MERCK LTD   STRIDES SHASUN LTD
EQUITY SHARE DATA
    MERCK LTD
Dec-16
STRIDES SHASUN LTD
Mar-17
MERCK LTD/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,0601,275 83.2%   
Low Rs623918 67.9%   
Sales per share (Unadj.) Rs632.4389.6 162.3%  
Earnings per share (Unadj.) Rs45.728.0 163.5%  
Cash flow per share (Unadj.) Rs62.348.9 127.4%  
Dividends per share (Unadj.) Rs11.004.50 244.4%  
Dividend yield (eoy) %1.30.4 318.5%  
Book value per share (Unadj.) Rs388.8303.1 128.3%  
Shares outstanding (eoy) m16.6089.42 18.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.8 47.3%   
Avg P/E ratio x18.439.2 47.0%  
P/CF ratio (eoy) x13.522.4 60.2%  
Price / Book Value ratio x2.23.6 59.8%  
Dividend payout %24.116.1 149.5%   
Avg Mkt Cap Rs m13,96998,036 14.2%   
No. of employees `0001.65.8 27.3%   
Total wages/salary Rs m1,4875,881 25.3%   
Avg. sales/employee Rs Th6,631.96,005.9 110.4%   
Avg. wages/employee Rs Th939.21,014.0 92.6%   
Avg. net profit/employee Rs Th479.4431.2 111.2%   
INCOME DATA
Net Sales Rs m10,49834,834 30.1%  
Other income Rs m2421,686 14.4%   
Total revenues Rs m10,74136,520 29.4%   
Gross profit Rs m1,1356,428 17.7%  
Depreciation Rs m2761,872 14.7%   
Interest Rs m02,269 0.0%   
Profit before tax Rs m1,1023,973 27.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m343470 73.0%   
Profit after tax Rs m7592,501 30.3%  
Gross profit margin %10.818.5 58.6%  
Effective tax rate %31.111.8 263.3%   
Net profit margin %7.27.2 100.7%  
BALANCE SHEET DATA
Current assets Rs m6,41038,165 16.8%   
Current liabilities Rs m8,82830,402 29.0%   
Net working cap to sales %-23.022.3 -103.4%  
Current ratio x0.71.3 57.8%  
Inventory Days Days5877 74.6%  
Debtors Days Days38104 36.7%  
Net fixed assets Rs m1,40637,639 3.7%   
Share capital Rs m166894 18.6%   
"Free" reserves Rs m6,28626,210 24.0%   
Net worth Rs m6,45527,105 23.8%   
Long term debt Rs m016,377 0.0%   
Total assets Rs m8,82881,168 10.9%  
Interest coverage xNM2.8-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.4 277.1%   
Return on assets %8.65.9 146.3%  
Return on equity %11.89.2 127.4%  
Return on capital %17.112.1 141.7%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m95913,465 7.1%   
Fx outflow Rs m2,6124,076 64.1%   
Net fx Rs m-1,6539,389 -17.6%   
CASH FLOW
From Operations Rs m1,0702,881 37.1%  
From Investments Rs m-750-7,051 10.6%  
From Financial Activity Rs m-1503,382 -4.4%  
Net Cashflow Rs m171-788 -21.7%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 37.8 48.1%  
FIIs % 1.0 8.6 11.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 25.9 112.4%  
Shareholders   28,591 56,241 50.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 25, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS